Trichosanthin (TCS), an active protein component isolated from a traditional Chinese medicinal herb Trichosanthes kirilowii, has been shown to inhibit HIV infection and has been applied in clinical treatment of AIDS. The recent development that chemokines and chemokine receptors play important roles in HIV infection led us to investigate the possible functional interaction of TCS with chemokines and their receptors. This study demonstrated that TCS greatly enhanced both RANTES (regulated upon activation, normal T cell expressed and secreted)– and stromal cell–derived factor (SDF)-1α–stimulated chemotaxis (EC50 ≅ 1 nM) in leukocytes (THP-1, Jurkat, and peripheral blood lymphocyte cells) and activation of pertussis toxin–sensitive G proteins (EC50 ≅ 20 nM). TCS also significantly augmented chemokine-stimulated activation of chemokine receptors CCR5 and CXCR4 as well as CCR1, CCR2B, CCR3, and CCR4 transiently expressed in HEK293 cells. A mutant TCS with 4,000-fold lower ribosome-inactivating activity showed similar augmentation activity as wild-type TCS. Moreover, flow cytometry demonstrated that the specific association of TCS to the cell membranes required the presence of chemokine receptors, and laser confocal microscopy reveals that TCS was colocalized with chemokine receptors on the membranes. The results from TCS-Sepharose pull-down and TCS and chemokine receptor coimmunoprecipitation and cross-linking experiments demonstrated association of TCS with CCR5. Thus, our data clearly demonstrated that TCS synergizes activities of chemokines to stimulate chemotaxis and G protein activation, and the effects of TCS are likely to be mediated through its interaction with chemokine receptors.
Trichosanthin (TCS),1 a 27-kd protein, is an active component extracted from the root tuber of Chinese medicinal herb Tian-Hua-Fen (Trichosanthes kirilowii) of the Cucurbitaceae family. In the classical Chinese medical reference work Compendium of Materia Medica written in the late 14th century, Tian-Hua-Fen was documented as a drug that resets menstruation and expels retained placentas, and has been used in medical practice in China for hundreds of years. In the early 1970s, TCS was isolated from T. kirilowii and has been used to terminate early and midtrimester pregnancies 1,2 and to treat ectopic pregnancies, hydatidiform moles, and trophoblastic tumors 2,3. Pharmacological studies reported that TCS is able to inactivate eukaryotic ribosomes 4,5 and to suppress the immune responses 6,7. More interestingly, TCS was shown to inhibit HIV replication in infected cells of lymphocyte and mononuclear phagocytic lineage, with no measurable toxicity in uninfected cells 8,9. In the early 1990s, TCS was applied in the treatment of patients with AIDS or AIDS-related complex in phase I and II studies 10,11,12,13. However, the underlying mechanisms of the activities of TCS are not yet well-understood.
Chemokines are a superfamily of small structurally related cytokine molecules characterized by their ability to induce leukocyte migration and related responses 14,15,16,17,18. Chemokines also play important roles in regulation of growth, and in angiogenic and developmental processes 14,19,20,21. Biological activities of chemokines are mediated by G protein–coupled chemokine receptors (GPCRs) classified as CC or CXC receptors based on the structures and types of chemokines they interact with 14,15. Of considerable interest is the recent discovery that CC chemokine receptors CCR5, CCR2B, and CCR3 and the CXC chemokine receptor CXCR4 are the essential coreceptors on the cell surface for HIV-1 fusion and infection 22,23,24,25,26,27,28. Substantial progress has been made recently in the understanding of chemokine receptor–mediated cellular signaling 29,30,31,32. Activation of chemokine receptors by chemokines induces downregulation of chemokine receptors on the cell surface 31,32. Prevention of HIV-1 infection and inhibition of HIV-1 replication by chemokines, antagonists of chemokine receptors, or mAbs to chemokine receptors, which induce downregulation of chemokine receptors and/or directly block HIV-1 interaction with the coreceptors, have been demonstrated 33,34,35,36,37. Therefore, drugs that target chemokine receptors, the coreceptors of HIV, have great potential in AIDS therapy.
This study was carried out in an attempt to understand the cellular and molecular mechanisms of the activities of TCS against HIV infection. Our results demonstrated that TCS profoundly augments the ability of different chemokines to activate a wide spectrum of chemokine receptors, leading to chemotaxis and G protein activation, and that the effect of TCS is likely to be mediated through its functional interaction with these chemokine receptors.
Materials And Methods
Recombinant human RANTES (regulated upon activation, normal T cell expressed and secreted), macrophage inflammatory protein (MIP)-1β, and monocyte chemotactic protein (MCP)-1 were purchased from Sigma Chemical Co., and stromal cell–derived factor (SDF)-1α was from PharMingen. Native TCS was isolated from T. kirilowii. Recombinant TCS (r-TCS) and a mutant of TCS (m-TCS) were prepared as described previously 38,39,40. The homogeneity of TCS preparations used was >98%. Rabbit anti-TCS antibodies and an mAb against TCS were provided by Prof. Ming Ye (Shanghai Institute of Cell Biology). Mouse mAb 12CA5 against the influenza hemagglutinin (HA) epitope was obtained from Boehringer Mannheim. [35S]GTPγS and [3H]cAMP were purchased from Amersham Pharmacia Biotech. MEM and RPMI 1640 were from GIBCO BRL. GDP and GTPγS were from Sigma Chemical Co. CNBr-activated Sepharose 4B was from Amersham Pharmacia Biotech.
CCR5 was cloned as described previously 32. The full-length cDNA encoding CCR1, CCR2B, CCR3, CCR4, and CXCR4 was cloned by reverse transcription PCR and PCR from THP-1 cells (for CCR1, CCR2B, and CXCR4) or PBL cells (for CCR3 and CCR4), using specific primers designed from the published sequences (available from EMBL/GenBank/DDBJ under accession nos. L09230, U03905, U28694, X85740, and X71635). The amplified human chemokine receptor cDNA fragments were then subcloned into a modified pcDNA3 vector (Invitrogen) with the sequence of the HA epitope tag at the 5′ end of the inserted receptor sequence. The authenticity of the receptor sequences was confirmed by DNA sequencing.
Cell Culture and Transfection.
THP-1 and Jurkat cells (American Type Culture Collection) were cultured in RPMI 1640 (GIBCO BRL) supplemented with 10% heat-inactivated fetal bovine serum (FBS; GIBCO BRL), 100 U/ml penicillin, 100 μg/ml streptomycin, and 2 mM glutamine. PBMCs were obtained by the Ficoll-Hypaque method from heparinized whole blood, and PBLs were derived by serial depletion of adherent cells and maintained in RPMI 1640 supplemented with 10–15% FBS. PBLs were stimulated with 5 μg/ml phytohemagglutinin for 1 wk and maintained thereafter in the presence of IL-2. Human embryonic kidney (HEK)293 cells (American Type Culture Collection) were cultured in MEM supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin, 100 μg/ml streptomycin, and 2 mM glutamine. Transient transfection of HEK293 cells was performed using 4 μg DNA/106 cells and the calcium phosphate–DNA coprecipitation method, and the transfected cells were used 48 h after transfection.
Chemotaxis was performed as described previously 41,42. In brief, cells were resuspended in RPMI 1640 containing 1 mg/ml BSA overnight in 5% CO2 at 37°C. 0.1 ml cells at 5 × 106/ml were added to the top chamber of a 24-well transwell (6.5-mm diameter, 5-μm pore size; Corning Costar) and incubated for 3 h or the time indicated at 37°C in 5% CO2. Cells passing through the membrane were collected from the lower well and counted by mixing a predetermined number of yeast with the cells and running them through a FACSCalibur™ flow cytometer (Becton Dickinson). The yeast and the cells were easily distinguishable on a side scatter vs. forward scatter plot, which allowed the calculation of the ratio of yeast to cells and the total number of cells that had migrated to the lower wells. Cell numbers were also determined using a cell counter and found to be in good agreement with the results from fluorescence-activated cell sorting.
[35S]GTPγS Binding Assay.
The assay was carried out as described 43,44. Cells were lysed in 5 mM Tris-HCl, pH 7.5, 5 mM EDTA, and 5 mM EGTA at 4°C. After the lysate was centrifuged at 30,000 g for 10 min, the membrane pellet was resuspended and aliquots containing 12 μg protein were incubated at 30°C for 1 h in 50 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM dithiothreitol, 5 mM MgCl2, 100 mM NaCl, 40 μM GDP, and 0.5 nM [35S]GTPγS (1,200 Ci/mmol) in the presence or absence of the agonists in a total volume of 100 μl. The reaction was terminated by adding cold PBS and filtering through GF/C filters. Radioactivity of each sample was measured in a liquid scintillation spectrophotometer. Data were means of duplicate samples. Basal binding was determined in the absence of agonists, and nonspecific binding was obtained in the presence of 10 μM GTPγS. The percentage of stimulated [35S]GTPγS binding was calculated as 100 × (cpmsample − cpmnonspecific)/(cpmbasal − cpmnonspecific).
Cells were challenged with agonists in the presence of 10 μM forskolin (Sigma Chemical Co.) and 500 μM 1-methyl-3-isobutylxanthine (IBMX; Sigma Chemical Co.) at 37°C for 10 min. The reaction was terminated with 1 N perchloric acid and then neutralized with 2 M K2CO3. The cAMP level of each sample was determined using radioimmunoassay as described previously 45,46,47. Data were averages of duplicate samples and were presented as a percentage of control, calculated as 100 × [cAMP(forskolin + agonist) − cAMP(basal)]/[cAMP(forskolin) − cAMP(basal)]. cAMP(forskolin + agonist) is cAMP accumulation in the presence of forskolin and agonist, cAMP(basal) is cAMP accumulation in the absence of forskolin and agonist, and cAMP(forskolin) is cAMP accumulation in the presence of forskolin alone.
Cells were incubated with TCS (100 nM) in PBS containing 2% BSA at 4°C for 1 h and, after washing with PBS, were incubated with 12CA5 (5 μg/ml) and rabbit TCS-specific antibodies (1:1,000) in PBS containing 2% BSA at 4°C for 1 h. The presence of HA-tagged chemokine receptors and TCS on the cell surface was detected by incubation with FITC-conjugated, affinity-purified goat anti–mouse IgG (Tago) and tetramethyl-rhodamine isothiocyanate (TRITC)-conjugated goat anti–rabbit IgG (Jackson ImmunoResearch Labs). The cells were analyzed on a FACSCalibur™ flow cytometer. Basal cell fluorescence intensity was determined with cells stained with the secondary antibody alone.
As described previously 48,49, cells grown on coverslips were fixed in 1% polyformaldehyde for 20 min. After incubation with TCS (100 nM) in PBS containing 2% BSA at 4°C for 1 h and washing twice with cold PBS, cells were treated with 12CA5 mAb and rabbit anti-TCS antibodies. The presence of HA-tagged chemokine receptors and TCS in the cells was then detected with FITC-conjugated, affinity-purified goat anti–mouse IgG and Texas Red–conjugated, affinity-purified goat anti–rabbit IgG (Amersham Pharmacia Biotech), respectively. In addition, control experiments with mock transfection, or in the absence of the first antibodies, or without TCS were performed. Images were recorded using a Leica TCS NT laser confocal scanning microscope.
SDS-PAGE and Silver Staining.
The experiment was performed by using a modified silver stain process. 5 μg purified protein was loaded to 12% SDS-PAGE. The gel was then prefixed with 30% ethanol and 10% acetic acid (HAc) and fixed in 30% ethanol, 0.4 M NaAc, pH 6.0, and 0.03% Na2S2O3. After washing, the gel was incubated in 0.1% AgNO3 and then in 2.5% Na2CO3 with 0.1% Na2S2O3. The reaction was terminated by incubating the gel in 10% HAc.
Immunoprecipitation, Western Blotting, and Cross-linking Experiments.
The immunoprecipitation experiment was performed as described 50,51. HEK293 cells grown in a 60-mm culture dish were lysed in 0.8 ml IP buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, and 0.4% digitonin) containing protease inhibitors on ice for 45 min. The lysate was centrifuged at 12,000 g for 30 min, and the supernatants were incubated with the 12CA5 antibody (0.5 μg) and protein A–Sepharose (GIBCO BRL) on ice for 2 h. TCS was then added (0.5 μg) and incubated for another 2 h. After washing with IP buffer, the immunocomplexes absorbed onto protein A–Sepharose were eluted in SDS-PAGE sample buffer (50 mM Tris-HCl, pH 7.4, 2% SDS, 5% 2-ME, 10% glycerol, and 0.01% bromophenol blue) and subjected to 10% SDS-PAGE and Western blot analysis. TCS present in the samples was detected using rabbit anti-TCS antibodies, and the presence of CCR5 on the same blot was detected using 12CA5 after stripping the antibodies off by incubating in 62.5 mM Tris-HCl, pH 6.7, 100 mM 2-ME, and 2% SDS at 70°C for 30 min.
Alternatively, the cell lysate prepared as described above was incubated with TCS-coupled Sepharose or BSA-coupled Sepharose (prepared following the manufacturer's instructions) on ice for 4 h. The supernatants were then discarded, the beads were lightly washed, and the protein absorbed onto the beads was eluted in SDS-PAGE sample buffer. SDS-PAGE and Western blot analysis were performed as described above.
The cross-linking was performed by using disuccinimidyl suberate (DSS; Pierce Chemical Co.) following the manufacturer's instructions. In brief, cells were lysed in 10 mM Hepes, pH 7.4, 5 mM EDTA, and 5 mM EGTA at 4°C. After the lysate was centrifuged at 30,000 g for 10 min, the membrane pellet was resuspended in PBS/Hepes (PBS containing 10 mM Hepes, pH 7.4). The aliquots containing 500 μg membrane protein were then incubated with or without DSS (100 μM) at room temperature for 30 min in the presence or absence of TCS (10 μg) in a total volume of 400 μl. The reaction was terminated by adding cold 1 M Tris-HCl (pH 7.4) to a final concentration of 10 mM and incubating for an additional 15 min. The samples were analyzed using Western blotting, and the cross-linked complex of TCS and chemokine receptors was detected by rabbit anti-TCS antibodies.
Each experimental point was performed in duplicate, and at least three independent experiments were carried out. Data are expressed as means ± SE of all determinations. Statistical significance of the experimental results was obtained by Student's t test. P < 0.05 was accepted as denoting statistical significance.
TCS Enhanced Chemokine-induced Chemotaxis in THP-1 Cells.
Chemotaxis is the prototypic function of chemokines, and thus serves as a biologically relevant functional in vitro assay for chemokine receptor activation 41,42. THP-1 cells are of human leukocyte origin and express functional CCR1 52, CCR5 53, and CXCR4 (Zhao, J., and G. Pei, unpublished observation), and therefore were used in the chemotaxis experiments. THP-1 cells showed a classic bell-shaped chemotactic response upon exposure to increasing concentrations of either RANTES (Fig. 1 A) or SDF-1α (Fig. 1 B), and both concentration–response curves reached maximum at 1 nM of chemokine (Fig. 1A and Fig. B). The presence of 2 nM TCS alone did not significantly affect chemotaxis (Fig. 1A–C). However, cotreatment of 2 nM TCS with RANTES or SDF-1α (0.1 nM and above) strongly increased cell migration induced by either chemokine (to ∼300% at chemokine concentrations of 1–10 nM). The concentration–effect curves of TCS on chemokine-induced chemotaxis show that a significant increase of RANTES- and SDF-1α–stimulated chemotaxis occurred at TCS concentrations of as low as 0.5 nM, and 2 nM TCS resulted in the maximal enhancement of ∼250% (Fig. 1 C).
TCS Enhanced Chemokine-induced G Protein Activation in THP-1 Cells.
Our previous study demonstrated that stimulation of chemokine receptors by their agonists activates membrane-associated Gi/Go proteins using [35S]GTPγS binding assay 32. As shown in Fig. 2A and Fig. B, RANTES (agonist of both CCR1 and CCR5) and SDF-1α (agonist of CXCR4) activated membrane-associated G proteins in a concentration-dependent manner in THP-1 cells. TCS (0.2 μM) alone did not have a significant effect on [35S]GTPγS binding. But interestingly, in the presence of 0.2 μM TCS, RANTES- or SDF-1α–stimulated G protein activation increased significantly and the maximal stimulation induced by RANTES and SDF-1α increased by 150 and 200%, respectively (Fig. 2A and Fig. B). As shown in Fig. 2 C, the ability of TCS to enhance chemokine RANTES- and SDF-1α–induced G protein activation was dependent on TCS concentration (EC50 ≅ 20 nM). At 5 nM or higher concentration, TCS showed a significant enhancement effect, and in the presence of 200 nM TCS, RANTES- and SDF-1α–induced chemokine receptor stimulation increased by two- to threefold. TCS alone did not have a significant effect on basal [35S]GTPγS binding (Fig. 2 C).
TCS Augmented Chemokine-induced Signaling in PBLs and Jurkat Cells.
To test whether TCS can enhance the capability of chemokine to activate chemokine receptors in other cells, PBLs and Jurkat cells were used in this study. As shown in Fig. 3A and Fig. B, TCS significantly enhanced the activation of G proteins induced by RANTES, MCP-1, and SDF-1α in PBLs and by RANTES and SDF-1α in Jurkat cells, respectively. Neither MCP-1 alone nor MCP-1 plus TCS resulted in any stimulation of G protein activation in Jurkat cells that lack CCR2, the receptor of MCP-1. This indicates that the specificity of the effects of TCS relies on both chemokine and chemokine receptor. In the chemotaxis assay, TCS also increased the efficacies of RANTES and MCP-1 to induce cell migration in PBLs (Fig. 3 C) and of RANTES and SDF-1α in Jurkat cells (Fig. 3 D). These data clearly demonstrate that TCS enhances the ability of chemokines to stimulate chemokine receptors and to induce chemotaxis in leukocytes.
The Effects of TCS Were Chemokine Receptor Dependent and Required G Proteins.
In HEK293 cells transiently expressing CCR5 (Fig. 4A and Fig. C) or CXCR4 (Fig. 4B and Fig. D), TCS significantly enhanced both RANTES- and SDF-1α–stimulated G protein activation. The effect of TCS in these cells was chemokine concentration and TCS concentration dependent. However, in the mock-transfected HEK293 cells, neither was chemokine-stimulated [35S]GTPγS binding observed nor did TCS show any augmentation effects when used together with RANTES or SDF-1α under the same conditions. In addition, MCP-1, an agonist of CCR2, in either the absence or presence of TCS, was not able to stimulate G protein activation in HEK293 cells transfected with CCR5 (data not shown). Chemokine receptors are able to couple to Gi and Gq proteins. Activation of chemokine receptors causes activation of membrane-associated G proteins and results in inhibition of adenylyl cyclase. As shown in Fig. 5, RANTES and SDF-1α caused inhibition of adenylyl cyclase activity in HEK293 cells transiently expressing CCR5 or CXCR4. Coapplication of TCS under such conditions considerably increased the efficacies of both chemokines to inhibit cellular cAMP production (Fig. 5). Chemokine-induced inhibition of cAMP production and the enhancement of this by TCS were abolished by pertussis toxin (data not shown). The above results further demonstrate the indispensability of both chemokines and the corresponding chemokine receptors for TCS to exert its effects.
The Effects of TCS Extended to Many Other Chemokine Receptors.
To test the potential effects of TCS on cellular signaling mediated by other chemokine receptors and GPCRs in addition to CCR5 and CXCR4, chemokine receptors CCR1, CCR2B, CCR3, and CCR4 and κ and δ opioid receptor were transiently expressed in HEK293 cells. As shown in Fig. 6, TCS significantly enhanced G protein activation mediated by CCR1, CCR2B, CCR3, and CCR4, but failed to enhance opioid agonist–induced G protein activation mediated by either κ (Fig. 6) or δ opioid receptor (data not shown). The above data suggest that in addition to CCR5 and CXCR4, TCS could exert its effect on other members of the chemokine receptor family, probably via a similar mechanism, but the effect of TCS is chemokine receptor specific and may not extend to other peptide Gi/Go-coupled receptors.
The Effects of TCS on Chemokine Receptor Activation Were Independent of Its Ribosome-inactivating Activity.
As shown in Fig. 6, after denaturation, TCS lost its ability to enhance chemokine receptor–mediated G protein activation. Furthermore, the enhancement effects of TCS were also blocked by preincubation with the purified mAb against TCS (data not shown). These experiments indicate that TCS is responsible for the observed magnification of chemokine-induced signaling. TCS was originally isolated from T. kirilowii, and the recombinant TCS with comparable activities was later successfully produced from Escherichia coli 38,39. As shown in Fig. 7r-TCS compared with native TCS conferred indistinguishable magnification effects on the chemokine-induced G protein activation and chemotaxis of leukocytes. These data argue that it is the presence of TCS, not any impurities from the preparation, that causes the observed effects on chemokine receptor activation and provides the molecular basis for structure–function studies of TCS.
TCS has been identified as a type I ribosome-inactivating protein (RIP) with a wide spectrum of biological and pharmacological activities. Recent studies showed that mutation at position 120–123 (Lys-Ile-Arg-Glu to Ser-Ala-Gly-Gly) in TCS causes a 4,000-fold decrease in ribosome-inactivating activity 54, implying that this region of the TCS molecule plays a critical role in maintaining its ribosome-inactivation activity. However, this very mutant of TCS (m-TCS) showed similar, or perhaps even higher, enhancement on chemokine-induced G protein activation and chemotaxis of leukocytes compared with native TCS (Fig. 7). These results indicate that residues 120–123 of TCS required for its ribosome-inactivation activity are not essential for the enhancement effects of TCS in the chemokine receptor–mediated signaling, and suggest that the effects of TCS we observed in this study are not related to its ribosomal inactivation.
Colocalization of TCS with Chemokine Receptors on the Membrane, and Interaction of TCS with Chemokine Receptors.
The ability of TCS to synergize chemokine-induced chemotaxis and G protein activation requires the presence of the chemokine receptors and may be accomplished through direct interaction of TCS with chemokine receptors on the membrane. To test this possibility, HEK293 cells were transiently transfected with control vector or HA-tagged CCR5 and incubated with or without 0.1 μM TCS. The HA-tagged chemokine receptors were labeled by staining the cells with 12CA5 and FITC-conjugated anti–mouse IgG, and TCS on the cell surface was detected with rabbit anti-TCS antibodies and TRITC-conjugated anti–rabbit secondary antibody. The results from flow cytometry are shown in Fig. 8 (A–D): typically, ∼30% of CCR5-transfected cells expressed CCR5 on the cell surface and were stained FITC fluorescence positive (Fig. 8 C). Strong TCS-specific TRITC fluorescence signal was detected in the CCR5-expressing cells (Fig. 8 D), and no significant positive TCS-like TRITC fluorescence was observed in the control vector–transfected cell population (Fig. 8 B). The immunofluorescence staining of TCS was also detected in the HEK293 cells expressing CXCR4 but not in the control cells (data not shown). These results indicate that the presence of chemokine receptors is a prerequisite for TCS binding to the cell surface.
The location of TCS and chemokine receptors on the surface of the cells expressing CCR5 and CXCR4 was visualized under a laser scanning confocal fluorescence microscope after staining with anti-TCS/anti–rabbit IgG–Texas Red and 12CA5/anti–mouse IgG–FITC. The visible binding of TCS (Fig. 8F and Fig. I) was only observed on the surface of the cells expressing either CCR5 (Fig. 8 E) or CXCR4 (Fig. 8 H), and it appeared, in more detail, that TCS was localized on the cell surface at the sites where the chemokine receptor CCR5 (Fig. 8 G) or CXCR4 resides (Fig. 8 J).
Finally, the interaction between TCS and chemokine receptors was investigated using several approaches. As shown in Fig. 9 A, chemokine receptor CCR5 in cell lysate was pulled down by the TCS-Sepharose but not by the BSA-Sepharose. Experiments done with chemokine receptor CXCR4 gave similar results (data not shown). Coimmunoprecipitation of TCS with chemokine receptors was also detected (Fig. 9B and Fig. C). In cross-linking experiments, incubation of TCS and membranes containing CCR5 with DSS resulted in an upshift of the TCS band to ∼70 kd, approximately the sum of TCS (29 kd) and CCR5 (50 kd) (Fig. 9 D). These results indicate that specific association of TCS to the cell membranes requires the presence of chemokine receptors, and that the synergic effects of TCS on chemotaxis and G protein activation induced by chemokines may be a result of direct interaction of TCS with chemokine receptors.
TCS has been used in the clinical treatment of patients with AIDS or AIDS-related syndromes, but its underlying mechanisms are not well-understood. Recent discoveries that the chemokine receptors CCR5, CXCR4, CCR2B, and CCR3 are HIV-1 coreceptors have thrown new light on the combat against AIDS and other viral diseases. In this work, the effects of TCS on chemokine-stimulated chemotaxis and cellular signaling events and the potential interaction of TCS with the chemokine receptors were investigated. Our results demonstrated that TCS significantly enhanced the chemokine-induced leukocyte chemotaxis, and that the effect of TCS was primarily due to its ability to synergize chemokine-dependent activation of chemokine receptors and subsequent receptor-mediated signaling. Our data also revealed the specific association of TCS to the cell membranes with the expression of chemokine receptors and the colocalization and coimmunoprecipitation of TCS with chemokine receptors, suggesting the possibility of direct interaction of TCS with chemokine receptors. Furthermore, the mutant TCS, which lacks the ribosome-inactivating activity, possessed similar enhancement activity as wild-type TCS. Taken together, these results brought to light that TCS was able to functionally interact with a broad spectrum of chemokine receptors as a potent coactivator, which may be one of the mechanisms underlying application of TCS in AIDS treatment.
Although our results demonstrated that TCS functionally interacts with chemokine receptors and is colocalized with the receptors on the cell surface, it remains unclear how TCS is able to costimulate the activation of many different kinds of chemokine receptors by their corresponding chemokines (such as RANTES, SDF-1α, MIP-1β, and MCP-1). One possibility could be that TCS induces the conformational change of chemokine receptors through direct physical contact at the putative binding site that possesses a common structural feature shared by these receptors. Alternatively, TCS may exert its effects through indirect interaction with a third partner on the cell surface, forming a complex capable of interacting with chemokine receptors. Our data suggest that on these chemokine receptors, the putative association site(s) at which TCS directly or indirectly interacts appears distinct from the site(s) associated with the chemokines. It has been shown that gp120 envelope glycoproteins of human HIV-1 can physically and functionally interact with chemokine receptors 36,55,56,57, and on the receptors the association site(s) of gp120 apparently overlaps with the site(s) associated with the chemokines, since gp120 is able to displace chemokines. Very recent reports from x-ray crystal studies have revealed the structural determinants of gp120 for its binding to CCR5 58. Similar approaches will be helpful in determining the structural domain of TCS essential for its association with chemokine receptors, since x-ray structural information for TCS is already available 59,60,61.
Several members of the chemokine receptor family function in association with CD4 to permit entry and infection of HIV-1. CCR5 is a major fusion coreceptor for macrophage-tropic HIV-1 isolates, and CXCR4 is a coreceptor for the entry of T cell line–tropic HIV-1 strains. Chemokines have been shown to inhibit HIV-1 infection, though inefficiently, by interacting with chemokine receptors and thus preventing HIV-1 from using the coreceptors 62,63. However, the clinical use of excess amounts of chemokines, which induce chemotaxis and activation of leukocytes, may result in undesirable inflammatory side effects. Recently, a CCR5 antagonist from RANTES derivatives has been shown in vitro to block HIV-1 infection of macrophage and lymphocytes at nanomolar concentration 34. Searching for potent antagonists of chemokine receptors is now popularly considered and heavily pursued as one of the most promising strategies for HIV therapy. The result from this study that TCS strongly enhanced the ability of chemokines to activate their receptors may further provide another useful approach to inhibit HIV infection. One of the potential advantages of using coactivators such as TCS could be that the agents, which are not agonists or antagonists, can effectively interact with a wide spectrum of chemokine receptors and may thus promote the efficiency of various endogenous chemokines in blocking HIV infection. It is also worth mentioning that very little about the coactivator(s) of GPCRs has been reported to date. Therefore, the enhancement effects of TCS on chemokine receptor activation may offer a good working model for augmenting our understanding of GPCR activation.
Trichosanthin is a member of the type I RIPs with RNA N-glycosidase activity. It has been reported that TCS inhibits HIV replication in vitro in acutely and chronically infected lymphocytes and monocytes 9. Clinical studies also show that TCS treatment may help to prevent loss of CD4+ cells in AIDS patients failing treatment with antiretroviral agents such as zidovudine 10 and even to increase CD4+ cells in other cases 11,12. It was speculated that the anti-HIV effects of TCS might be due to its ribosome-inactivating activity. However, studies suggest that the mechanism of TCS to inhibit the replication and infection of HIV-1 is different from its activities of ribosome inactivation and immunomodulation 40,64. In addition, the undesirable side effects of TCS, which have seriously limited its clinical application, may also be related to its activity to induce unwanted cytotoxicities and allergic reactions. Our data in this study showing that TCS greatly enhances activation of chemokine receptors independent of its RIP activity may not only reveal an alternative mechanism underlying the anti-HIV effects of TCS but may also provide a mutagenesis strategy potentially to improve its therapeutical effectiveness and to reduce its side effects.
The authors wish to thank Prof. Ming Ye for providing rabbit anti-TCS antibodies, Prof. Zhi-Jiang Wu for PBL cell culturing, Dr. Guo-Xiang Wu for technical support on cloning CXCR4, Ms. Ru Zhang for technical assistance with Western blotting, Dr. Zhi-Jie Cheng for helpful discussion, and Dr. Jun Guo, Xu-Ming Zhang, and Pei-Hua Wu for their help in preparing this manuscript.
This research was supported by research grants from the National Natural Science Foundation of China (39630130, 39625015, and 39825110), the Chinese Academy of Sciences (KJ951-B1 and KY951-A1), and the German Max-Planck Society.
1used in this paper: DSS, disuccinimidyl suberate; FBS, fetal bovine serum; GPCR, G protein–coupled receptor; HA, hemagglutinin; HEK, human embryonic kidney; MCP, monocyte chemotactic protein; MIP, macrophage inflammatory protein; RANTES, regulated upon activation, normal T cell expressed and secreted; RIP, ribosome-inactivating protein; SDF, stromal cell–derived factor; TCS, trichosanthin